Suboxone Tooth Decay Lawsuit: Suboxone Lawsuits (September 2026)

Suboxone, a medication for dealing with opioid addiction and treating withdrawal symptoms, can be a lifesaver. It helps by stopping cravings and making it difficult to get high on other dangerous drugs while taking it.

But lately, there has been a worrying discovery—a link between Suboxone sublingual strips and serious dental issues, such as the risk of severe tooth decay. Remember that only the oral film version of Suboxone causes tooth decay.

If you or someone you care about has had dental issues, such as tooth loss or gum injuries, while on prescription Suboxone film, we might be able to assist with obtaining compensation.

The Suboxone lawsuit lawyers at Dolman Law Group support Lawsuit Legal News, and we are here to help you determine your rights and what steps you can take to cover your medical bills and rebuild your life.

Contact us online or call us at 866-535-9515 to decide whether or not you qualify to file a lawsuit.

Recent Suboxone Update—April 2026

We expect this to be a fast-moving case. The science linking sublingual Suboxone to tooth loss and other dental injuries appears strong. Of course, we will have to wait until both sides present their case, either to a jury or through mediation, but as it stands, we are confident in the claims made against Indivior.

Where can I get the latest update on the Suboxone lawsuit?

This page is an excellent resource for anyone looking to keep up with the latest news in the Suboxone lawsuit. We will provide easy-to-understand summaries of any court decisions, updates on any progress or changes in the case, and information about the potential settlement of the Suboxone case. We will also report on any new dental injuries that may arise in this case.

As Suboxone tooth decay lawsuits continue to be filed and the consolidated federal case against Suboxone (known as an MDL) progresses, the team at Lawsuit Legal News will provide regular and timely updates to keep you informed.

Our goal is to provide the most accurate and up-to-date information on all sites on the internet. If you have suffered severe tooth loss and decay while taking Suboxone sublingual strips, we want this page to be your go-to resource for new information. 

Here are the latest updates on the lawsuit:

[Upcoming] June 1, 2026: Deadline Set for Older Cases to Fix Missing Paperwork

The court has set a June 1, 2026 deadline for older Suboxone cases, specifically those filed before 2025, to correct missing or incomplete paperwork. This is another step in cleaning up the docket. Cases that fail to comply risk dismissal, as the court continues pushing to move only supported claims forward.

April 22, 2026: Judge Pressures Providers Over Missing Records

The litigation hit a serious slowdown this spring due to missing dental and medical records. After ongoing delays, Judge Calabrese held a Show Cause hearing on April 22, 2026, demanding answers from providers who failed to comply with discovery orders. The court signaled it may consider sanctions, as these delays continue to hold up progress for plaintiffs.

April 20, 2026: Plaintiff Fact Sheet Deadline Forces Case Screening

April 20, 2026 marked a critical deadline for plaintiffs in the discovery pool to submit detailed Plaintiff Fact Sheets. These filings are essential to prove dental injuries and Suboxone use. Cases that failed to meet the requirement are likely facing dismissal, while defendants now have until May 20 to respond with their own disclosures.

March 2026: MDL Census Reveals Over 5,700 Active Claims

While the official MDL docket lists around 1,800 cases, early 2026 filings revealed the true scope is much larger. The Schedule A census shows more than 5,700 active claims tied to Suboxone tooth decay. At the same time, the court has been aggressively dismissing unsupported claims, cutting more than 2,200 cases in the first quarter alone.

February 26, 2026: Court Establishes Core Discovery Pool of 100 Cases

The Suboxone tooth decay MDL took a major step forward on February 26, 2026, when Judge J. Philip Calabrese created a 100-case “Core Discovery Pool.” These cases were selected from an initial group of 500 and will move into intensive discovery. This is the proving ground for the litigation, with future bellwether trials expected to come directly from this group.

December 1, 2025 - Slight Decline in Suboxone Lawsuit Count

As of early November 2025, the number of Suboxone tooth damage lawsuits filed in federal court stands at 1,871, down slightly from the 1,877 reported last month. The small decrease reflects a mix of new filings and recent dismissals as the multidistrict litigation (MDL) continues to evolve.

Judge Allows Plaintiff to Proceed Despite Missed Deadlines

In a recent ruling, the MDL judge allowed a Suboxone plaintiff to move forward after initially missing court deadlines. The plaintiff, Michelle Robinson, was incarcerated for much of 2025 and unable to complete her required submissions on time. After her release in October, she submitted the necessary documentation. The court found she had shown good cause for the delay and denied the motion to dismiss her case.

This decision shows that while the court expects timely compliance, it is also willing to consider individual circumstances when legitimate reasons are provided.

Stay Informed About the Suboxone Litigation

Lawsuit Legal News continues to monitor the Suboxone litigation closely. With bellwether trials on the horizon and more than 11,000 plaintiffs involved behind the scenes, each update helps clarify the path ahead.

If you have questions about Suboxone-related tooth damage or want to stay informed about the legal process, the LLN team is here to help. Visit us often for the latest litigation developments.

November 1, 2025 - Judge Tightens Rules as Litigation Grows

Last month, the federal judge overseeing the Suboxone tooth decay multidistrict litigation (MDL) issued new orders aimed at streamlining the rapidly expanding case load and improving transparency from drugmakers Indivior and Aquestive. It’s estimated that more than 11,000 plaintiffs allege that the dissolvable Suboxone film caused severe dental injuries, including tooth decay and loss. While the docket officially lists fewer than 2,000 cases, many include dozens of plaintiffs filed in batches.

New Orders Target Recordkeeping and Manufacturer Disclosures

Judge Philip Calabrese now requires all plaintiffs who file after October 1, 2025, to submit census forms within 60 days. Older cases must meet a June 1, 2026, deadline. These forms are critical for tracking plaintiff data and moving viable cases forward.

In addition, the court ordered Indivior and Aquestive to produce key internal records, including FDA filings, marketing materials, and reports of dental injuries, to help determine what the companies knew about Suboxone’s risks.

Stan Gipe’s Role on the Plaintiffs’ Steering Committee

Attorney Stan Gipe of Dolman Law Group was appointed to the Plaintiffs’ Steering Committee to help guide the national litigation strategy. His work includes managing discovery issues, overseeing document production, and helping identify strong bellwether cases. Dolman Law Group created Lawsuit Legal News to provide updated information on pending mass tort litigation.

What to Expect Next

With bellwether trials approaching, pressure is building. A global Suboxone settlement isn’t expected until 2026, but these recent developments show the court is working to clear delays and force accountability. Lawsuit Legal News will continue to report as the litigation progresses, but if you have any questions, reach out for more information.

October 1, 2025 - Enforcement Ramps Up, Case Count May Be Nearing 20,000

Federal Judge Cracks Down on Delays

The Suboxone tooth decay litigation entered a more aggressive phase this month as Judge J. Philip Calabrese signaled he’s done tolerating missed deadlines and ignored court orders. During the September 9 status conference, the judge addressed procedural slowdowns and issued new warnings to both plaintiffs and third-party providers.

Three outside providers who failed to comply with record subpoenas will now be required to turn over documents or risk Rule 45 contempt proceedings, which can include court sanctions. Separately, the court dismissed with prejudice a number of plaintiff cases due to noncompliance with prior court orders. These dismissals are permanent, and the cases cannot be refiled.

While these steps may sound harsh, they are expected to benefit compliant plaintiffs by clearing out stale or unsupported claims and keeping the MDL moving toward bellwether trials and eventual settlement.

Plaintiff Census and Record Collection Update

The judge also announced that Census Round 2 will begin soon. These census forms help identify viable claims by collecting essential treatment and prescription information. Plaintiffs who fail to submit the required information risk losing their claims.

True Suboxone Case Count Might Top 20,000

Although the official MDL docket shows 1,882 filings, the actual number of individual plaintiffs is far higher due to batch-filing rules. Under a prior order, lawyers can include up to 100 plaintiffs per complaint. Based on current estimates, there may now be over 20,000 individual claims in the MDL—though not all will qualify for compensation.

Settlement Timeline Still Points to 2026

Despite some public speculation about an early resolution, most legal analysts continue to believe that a Suboxone settlement won’t happen until sometime in 2026. That’s when bellwether trials are expected to apply real pressure on Indivior, the drug’s manufacturer, to settle rather than face juries who will hear detailed evidence of the drug’s alleged dental harm.

September 2, 2025 - Timeline and Schedule Update for Suboxone Tooth Damage Lawsuit

The timeline of the multidistrict litigation for the Suboxone tooth decay lawsuits has changed a bit since we last discussed it, so we wanted to provide you with an update on what you can expect regarding upcoming proceedings. 

Here’s where things stand now:

As we discussed below, Judge Calabrese held a ‘show‑cause hearing’ to find out why certain pharmacies have not complied with an earlier order to provide records to the court. 

These records are vital for moving forward to the Bellwether Trials since they show who was prescribed Suboxone, when they began taking the sublingual films, and how long they were on the medication. Without these records, the litigation can’t move forward effectively. If Walgreens does not get the records together soon, they could be sanctioned by the court for their delay.

Bellwether Trials: The handful of trials that will act as gauges for both sides, known as bellwether trials, are now projected to begin in late 2025 or early 2026. These test cases play a huge, make‑or‑break role in the overall MDL settlement negotiations since they will give both sides valuable information about how juries are responding to the details of the Suboxone lawsuits.

Discovery Continues: At the current moment, although not much is happening in the public eye, there are still lots of things going on behind the scenes. Indivior is working on gathering its internal documents and other proof that it did not act negligently, while the plaintiffs are preparing depositions that will primarily focus on Suboxone’s 2022 label change, their marketing practices, and what they knew about the oral health concerns, when they knew it, and why they waited so long to add warnings to their products.

What’s Next In Suboxone MDL?

September 9, 2025: On Sep 9, an in-person hearing will be held to update the court and address any case management issues.

The court will also hold a status conference on this day for the Suboxone MDL, which we haven't had in a while. At this conference, both sides will update the court on their progress, address any procedural matters, and discuss the next steps, such as discovery updates and potential bellwether trials.

September 29, 2025: As September closes, the Court’s deadline for both sides to submit their fact sheets arrives. These fact sheets outline each side’s arguments. 

For the plaintiffs, the fact sheets will include legal documents that summarize each plaintiff’s history with Suboxone, their dental injuries, and other relevant medical history. The defendant’s fact sheets will include their responses and defenses to the plaintiffs’ claims. 

These fact sheets help both the court and the attorneys identify patterns across cases, which is essential for deciding which cases will be selected for the bellwether trials.

September 1, 2025 - Court Questions Pharmacies for Not Providing Records On Time, Increase in Batch Filings

On August 26, 2025, Judge Calabrese held a short but pointed show-cause hearing addressing four medical providers who failed to comply with previous court orders to turn over Suboxone-related records. Plaintiffs’ attorneys described months of outreach, including certified mail and repeated phone calls, without receiving the required documentation.

No representatives from the noncompliant providers appeared at the hearing. The court took the matter under advisement and directed the Clerk to send a copy of the hearing minutes to each entity. Plaintiffs also requested that the court impose monetary sanctions and require reimbursement of the legal costs incurred during the pursuit of these records.

Without pharmacy and provider records, plaintiffs cannot prove that they were prescribed Suboxone film, an essential element of these dental injury claims. The court’s willingness to consider sanctions may help break the impasse and push the litigation toward trial readiness.

Suboxone Filings Gain Traction in Batches

A new joint complaint filed in the MDL includes 54 plaintiffs from across the country. Each alleges severe dental injuries, such as tooth decay, erosion, and extractions caused by long-term use of Suboxone film, prescribed either for opioid use disorder or pain management.

The lawsuit claims the drug’s manufacturers failed to warn of Suboxone’s acidic formulation and its connection to irreversible dental damage. Plaintiffs say these risks were known to the company and supported by internal reports and scientific publications, but warnings were not added until June 2022, and only because of an FDA mandate.

If you were prescribed Suboxone and suffered serious dental problems, you may be eligible to join this litigation. The Lawsuit Legal News team can answer any questions and explain your rights during a free consultation.

August 1, 2025 - Status Conference Yields Key Progress, Invidior May Be Misjudging Public Opinion

Recently, the MDL judge held a two-hour Zoom status conference to track the progress of the Suboxone tooth decay litigation. The result? Some key agreements and deadlines show that this case is moving forward.

Agreements reached:

• How to handle missing documents from plaintiffs
• Redacting older deposition transcripts
• Finalizing authorization forms for treatment records
• Tracking claims filed after October 7, 2024
• Managing future document production from relevant individuals

Upcoming deadlines:

• August 15, 2025 – Propose a plan for collecting documents from non-custodial sources or identify any disagreements
• September 29, 2025 – Submit fact sheets summarizing each side’s claims and defenses

The next in-person hearing is scheduled for September 9, 2025.

Deposition Procedures Finalized

On July 8, a new order outlined the rules for all upcoming depositions in the Suboxone MDL. Highlights include:

• In-person depositions are the default; Zoom is allowed if both sides agree
• Remote depositions must be secure and private
• Exhibits must be shared with witnesses ahead of time when possible
• Defense must offer two available dates within 10 days when plaintiffs request to depose company personnel
• Each side gets one lead examiner per deposition; plaintiffs can split questioning between two attorneys with advance notice

Settlement Strategy: Indivior’s Risky Gamble

Indivior seems to believe juries won’t sympathize with Suboxone users in recovery. That assumption may backfire—badly.

• These plaintiffs are teachers, nurses, warehouse workers, single parents, basically regular people who followed their doctors’ treatment plans and trusted Suboxone.
• Instead, they ended up with severe dental injuries, including broken teeth, chronic pain, and in some cases, complete dentures by age 40.
• Jurors won’t ignore that. If Indivior thinks stigma will protect them in court, they’re misreading the cultural moment—which could cost them billions.

Suboxone Cases Are Gaining Visibility

SuboxSuboxone lawsuits have flown under the radar—until now. The tide is turning.

• As more people in recovery speak out, the emotional weight of their stories is gaining traction.
• Many had no history of dental problems before taking Suboxone.
• Now they face thousands of dollars in unreimbursed dental care, lost confidence, and lasting pain, after receiving no warning from the drugmaker.

A single high-profile trial could make this litigation national news and put real pressure on Indivior to settle.

July 1, 2025 - Records Delays, Plaintiff Changes, and Settlement Timeline Insights

As the Suboxone tooth decay litigation gains momentum, several key developments are shaping the road ahead for victims seeking justice. From pharmacy records delays to updates on trial preparations and the timeline for potential settlements, here’s what’s happening now—and what it means for you.

Pharmacy Record Access Still a Hurdle

Obtaining pharmacy records continues to be a frustrating roadblock for many plaintiffs. These records are essential for proving Suboxone use, but not all pharmacies are cooperating. Last month, the court issued a show-cause order against Walgreens, Safeway, and Porch Light Health for allegedly failing to produce records within 30 days, as required by Case Management Order No. 13.

This week, the judge dropped the order for Safeway and Porch Light after confirming their compliance, but Walgreens remains on the hook. A hearing is set to determine whether the retail giant has been meeting its legal obligations. For plaintiffs trying to move their cases forward, these delays are more than a nuisance; they can hold up everything..

Plaintiff Pool Refreshed in Trial Prep Process

Recently, 48 plaintiffs were removed from the initial 500-person Records Collection Pool due to voluntary dismissals or failure to submit required documentation. These individuals have now been replaced with new plaintiffs, randomly selected according to the established trial protocol.

This is important because these 500 cases form the backbone of the bellwether trial (test trials) selection process. From this pool, 100 will move to deeper discovery, and eventually, four key cases will go to trial. This ongoing refinement keeps the MDL on track and ensures that well-documented, trial-ready cases rise to the top.

We Don’t Expect a Suboxone Settlement Just Yet

If you’re wondering when settlement payouts might begin, the short answer is... no time soon. While there’s always buzz about early deals, the more realistic expectation is that meaningful settlement talks won’t pick up steam until late 2025 or even early next year.

Why the delay? Defense attorneys for Indivior, the maker of Suboxone, are likely waiting for the three-year statute of limitations to expire, which should be around now. Settling too early could trigger a wave of new lawsuits, which the company would rather avoid. Waiting allows them to limit risk and control the number of claims. To learn whether you still have a viable Suboxone claim, reach out to the LLN team today.

June 1, 2025 - Suboxone Litigation Moves Toward First Trials as Case Count Nears 900

Plaintiffs across the country allege that Suboxone film, a medication used in opioid addiction recovery, caused severe tooth decay and dental injuries, and that the manufacturer, Indivior, failed to adequately warn of this risk.

New Case Management Order Sets Bellwether Trial Process

On May 30, the MDL judge issued Amended Case Management Order No. 15, outlining a detailed structure for selecting bellwether trial cases. The order creates a 500-member Records Collection Pool, from which plaintiffs must submit medical authorizations to verify Suboxone treatment and related dental harm. Noncompliant cases may be dismissed and must be promptly replaced to maintain the pool size.

From this group, 100 cases will be randomly selected to move into the Core Discovery Pool, where both sides will exchange fact sheets and medical documentation through the secure Rubris Crosslink platform. That group will be narrowed to 50 cases, balanced between randomly chosen, plaintiff-selected, and defense-selected plaintiffs. 

After discovery and depositions, 15 cases will form the Trial Pool—five selected by each side and five randomly chosen. Finally, six potential trial cases will be named, with each party striking one to finalize four bellwether trials. All trials will proceed as single-plaintiff cases.

The Stakes for Indivior

As this litigation progresses, legal observers warn that Indivior may be miscalculating its exposure. The company appears to be betting that jurors will lack sympathy for individuals recovering from addiction. But plaintiffs’ attorneys strongly disagree. They argue jurors will see past outdated stigmas and focus on the fact that these are real people—parents, workers, and spouses—who got clean and trusted Suboxone to help them stay there.

Instead, many were blindsided by painful, costly dental injuries. From broken and rotting teeth to repeated dental surgeries and tens of thousands in out-of-pocket costs, these stories are powerful. Plaintiffs claim Indivior never warned about this risk, leaving patients vulnerable to permanent harm.

Should these cases proceed to trial, attorneys believe juries will empathize with victims and that any attempt to downplay their suffering could backfire significantly. A fair early settlement, they argue, would likely cost Indivior far less than letting this play out in front of sympathetic jurors.

Case Count Update: More Lawsuits on the Way

As of early May, the MDL had grown to 896 cases, up from 884 the previous month. But this modest increase doesn’t reflect what’s coming. Lawyers are now filing complaints in blocks of 100 plaintiffs per suit, meaning a large surge is expected in June.

May 1, 2025—Suboxone Dental Injury Lawsuits Status

Hundreds of individuals have filed lawsuits alleging that Suboxone, a medication used for opioid use disorder, caused severe dental damage, including tooth decay and tooth loss. These cases are now part of coordinated federal litigation in Ohio.

Overview of the Suboxone MDL

• MDL Number: 3092
• Location: U.S. District Court for the Northern District of Ohio
• Presiding Judge: J. Philip Calabrese
• Case Volume: As of May 1, 2025, approximately 896 Suboxone dental injury cases are consolidated in this MDL.
• Trial Status: No bellwether trials have been scheduled or held yet. Settlement discussions have not led to any approved resolutions at this time.

Recent Key Developments

• Mass Filing Streamlined:
  • The court approved Case Management Order No. 14, allowing up to 100 plaintiffs to be included in a single complaint.
  • This order was designed to reduce filing fees and manage the growing number of incoming cases more efficiently.
• Discovery Advancing Toward Bellwether Trials:
  • By mid-April, attorneys on both sides had selected a group of 500 plaintiffs for targeted discovery.
  • This process includes collecting dental records and treatment history to help identify cases for future bellwether trials.
  • Discovery efforts are expected to inform the eventual selection of test cases later in 2025.
• Depositions and Corporate Accountability:
  • Plaintiffs intend to take corporate depositions under Rule 30(b)(6) from Indivior, the manufacturer of Suboxone.
  • Topics include:
    • The company’s response to dental injury complaints from Suboxone users.
    • Details surrounding the 2022 label update ordered by the FDA, which added a warning about dental risks.
    • The structure of Indivior and any related corporate entities involved in Suboxone's development and distribution.
• Third-Party Discovery Enforcement:
  • At a status conference held on April 17, 2025, the court addressed discovery delays.
  • Judge Calabrese scheduled a show-cause hearing for CVS Pharmacy, which had failed to comply with a subpoena for patient records relevant to the litigation.

What Comes Next

• The litigation remains in the pre-trial discovery phase, with no trial dates set yet.
• Regular status conferences keep the case on track.
• Bellwether case selection is expected to begin once the discovery phase for the initial plaintiff pool is complete.

This MDL reflects growing legal scrutiny of the potential dental harm associated with Suboxone, particularly following the FDA's 2022 label change that acknowledged dental risks. More filings are expected as awareness of the litigation spreads.

Earlier Suboxone Litigation News

As of February 2024, the Suboxone Multidistrict Litigation (MDL) was created to consolidate all federal cases for pretrial procedures. The MDL is following the typical process for dangerous drug lawsuits. Both sides are holding their positions and asking the court to grant motions in their favor. Discovery continues while more evidence is gathered to support the link between Suboxone use and the serious dental problems many plaintiffs face. 

New cases are joining the MDL each month as more Suboxone users are discovering the link between the drug and their injuries. We are currently accepting clients who have experienced at least three lost teeth from Suboxone use, either from a dental extraction or from falling out. 

---

April 1, 2025—Suboxone Dental Injury Litigation: Growth, Strategy, and Defense Tactics

Volume and Coordination

The last 30 days confirm that the Suboxone dental injury litigation is expanding rapidly and becoming more organized. The MDL’s innovative filing and case management orders are streamlining what could have been a chaotic influx of thousands of individual suits​. For us, this means it’s now easier to add new cases to our files (lower fees and direct MDL filing). Still, it is also vital to diligently follow MDL procedures, ensuring that each client’s facts are correctly documented in joint complaints, etc.

We are mindful of the upcoming June 2025 cutoff for filings – Judge Calabrese explicitly warned that without a tolling deal, every case must be filed to preserve claims​. Practically, we are racing against the clock this spring to sign up clients and bundle their filings before any statute runs. The court’s willingness to accommodate bulk filings is a boon, but it also expects compliance and organization. We see a trend of close judicial supervision: monthly status conferences, detailed orders on evidence gathering, and an explicit schedule for moving cases forward.

Bellwether Strategy

Both plaintiffs and defendants are now gearing up for the bellwether trial phase. The selection of 500 candidate cases and the narrowing process is essentially a vetting of the strongest examples on each side​. Plaintiffs’ firms should strategize: which of their cases might be picked, and how to best position them (complete medical records, expert evaluations of dental damage, etc.).

Defense counsel, on the other hand, will analyze which claims seem most defensible or most severe. In the next few months, we may see jockeying over which specific cases are included in the bellwether pool. The March 14 orders indicate that Judge Calabrese wants a fair cross-section of cases—likely including a mix of demographics, durations of Suboxone use, and extent of dental injury—rather than just hand-picked extremes.

The implication is to prepare every case as if it could be that first trial. Being selected as a bellwether can spotlight a firm’s client, for better or worse, so readiness is key. The first bellwether trials, expected in late 2025, will heavily influence settlement values for all other cases. A significant plaintiff verdict could pressure Indivior to settle en masse, whereas a defense win might curb the momentum. Thus, the next 6-8 months are critical: it’s when evidence is gathered and test cases are chosen, effectively setting the stage for global settlement talks or protracted trial battles.

Defendant’s Posture

Indivior’s strategy in recent weeks appears to be resisting broad concessions and testing plaintiffs’ resolve. They opposed a blanket tolling agreement (which would have led to a flood of filings) and had earlier tried to knock out claims via preemption, but the court largely denied this. Internally, Indivior is likely assessing its exposure: with about 10,000+ lawsuits already filed or bundled​, the potential liability could be significant. One notable factor is the profile of the plaintiffs – many are recovering opioid addicts treated with Suboxone.

The defense may hope that juries will be less sympathetic to such individuals or attribute their dental issues to poor personal health. However, we counter that these are highly sympathetic stories: people who got clean from opioids only to have Suboxone ruin their teeth​. In the past 30 days, some commentary, including from the bench, hinted that underestimating these plaintiffs could be a costly mistake for the defense.

We may see Indivior pivot to a more conciliatory approach if the case counts continue to rise, for instance, engaging in mediation talks later in 2025 after a few bellwether cases are prepared. For now, however, no settlement overtures have been reported. Indivior defends each case, hires expert dentists to argue other causes of decay, and so on. Their liability insurance and financial statements, as noted in recent filings, acknowledge the MDL. Still, the company insists Suboxone is safe when used as directed (apart from the known risks now on the label).

March 1, 2025—Suboxone Tooth Decay MDL Update

The Suboxone multidistrict litigation (MDL 3092) is expected to gain significant momentum in the coming months. The June 2025 deadline marks the expiration of the statute of limitations (SOL) for failure-to-warn claims in states with two-year filing deadlines. Since the warning label for Suboxone sublingual films was updated in June 2022, any claims in those states must be filed by June of this year.

The Suboxone tooth decay lawsuits are consolidated in MDL No. 3092 in the U.S. District Court for the Northern District of Ohio. The litigation continues to expand rapidly, with 896 pending lawsuits as of early February 2025—an increase of 142 cases since January. This sharp rise suggests that more individuals are coming forward as awareness of Suboxone’s dental risks spreads.

Recent Individual Lawsuit Filings

New lawsuits continue to be filed across the country. Below are two notable recent cases:

• Suboxone Boston Case
  A plaintiff in Boston, Massachusetts, alleges that prolonged Suboxone film use, even as prescribed, led to severe dental injuries. Despite no prior history of dental problems, the individual suffered:
  • Rapid tooth decay
  • Multiple root canals
  • Crowns and extractions

The lawsuit blames Suboxone’s acidic formulation, which dissolves under the tongue, for eroding tooth enamel and causing irreparable damage. This case underscores a recurring theme—patients followed prescription guidelines and maintained oral hygiene yet suffered serious harm due to insufficient warnings.

• Pennsylvania Suboxone Case
  A Pennsylvania resident filed a lawsuit citing similar injuries. The plaintiff contends that Suboxone film use led to:
  • Severe and permanent dental damage
  • Rampant cavities
  • Cracked teeth
  • Oral infections and tooth loss

The lawsuit attributes these injuries to Suboxone’s prolonged low-pH exposure in the mouth, which weakened enamel and promoted decay.

These lawsuits reflect a broader nationwide trend, with plaintiffs asserting that Suboxone’s design and method of use—dissolving a highly acidic film in the mouth daily—caused extensive dental damage. They argue that proper warnings or a safer alternative formulation could have prevented these injuries.

MDL Status and Case Management

With the motion to dismiss primarily resolved, the Suboxone MDL is now transitioning into the discovery and bellwether phase:

Discovery Orders & Case Management Developments

• New Discovery Orders (February 2025):
  • The court issued new rules to streamline the collection of dental and medical records.
  • A February 21, 2025, order mandates that healthcare providers accept standardized authorization forms and produce records within 30 days or face contempt under Federal Law. R. Civ. P. 45.
  • The goal is to expedite the collection of evidence related to the plaintiffs' dental history and injuries.
• Status Conferences & Trial Preparation:
  • A status conference was held on February 12–13, where legal teams discussed:
    • The scope of discovery (including electronically stored information custodians).
    • The process for selecting bellwether cases for early trials.
  • The court has directed all parties to cooperate on discovery matters, including electronic records and medical documentation.
• Upcoming Key Dates:
  • An informal working session is scheduled for March 10, 2025, to address ongoing discovery issues.
  • The next official status conference is set for March 11, 2025.

These procedural developments mark substantial progress in the MDL. They ensure that cases move forward efficiently while establishing a framework for early bellwether trials.

As the litigation expands, new filings are expected to continue increasing, especially as the June 2025 filing deadline approaches in certain states. The court’s focus on discovery and record collection indicates that this MDL is moving closer toward key pre-trial milestones and potential bellwether trials.

February 1, 2025 - Suboxone MDL Reaches 754 Cases with 38 New Filings

The Suboxone multidistrict litigation (MDL) in the Northern District of Ohio has expanded to 754 active cases, marking a 38% increase since December 2024. With the statute of limitations potentially expiring in June 2025, particularly in states with a three-year limit, there is an anticipated surge in filings.

Individuals alleging that Suboxone, an opioid addiction treatment, has led to severe dental issues such as tooth decay and erosion are urged to file their claims promptly. U.S. District Judge Philip Calabrese, overseeing the MDL, has indicated that the court is preparing for this influx. Due to the absence of a tolling agreement between plaintiffs and defendants, each claimant must submit their lawsuit individually before the deadline.

January 1, 2025 - Key Updates in Suboxone Tooth Decay Lawsuits: Legal Actions and Scientific Findings

As of January 2025, there have been notable advancements in the ongoing Suboxone tooth decay litigation:

Case Expansion and Multidistrict Litigation (MDL):

Surge in Lawsuits: The Suboxone MDL now includes 716 active cases, following the addition of 38 new lawsuits. This represents a significant jump from just four cases filed in October, signaling a growing wave of claims against the manufacturers.

Court Proceedings and Legal Motions:

Motion to Dismiss Hearing: On December 16, 2024, Judge J. Philip Calabrese presided over arguments related to Indivior's motion to dismiss. Indivior asserts that federal law overrides state-level claims concerning insufficient warnings. The judge's ruling on this matter is expected to have a substantial impact on the trajectory of the litigation.

Plaintiff Documentation and Requirements:

Census Protocol Initiation: A recent case management directive requires plaintiffs who filed claims by October 7, 2024, to submit detailed information and authorizations through the Rubris Crosslink system. This process is designed to validate Suboxone Film usage and related dental damages, ensuring that claims are properly supported.

Scientific Research Highlights:

Acidity Concerns and Dental Risks: Studies have shown that Suboxone sublingual films contain highly acidic properties, which may accelerate dental erosion and decay. With acidity levels reportedly 10 times higher than tomato juice, researchers believe this could explain the widespread reports of severe dental issues among users.

These latest updates reflect the dynamic progression of Suboxone-related lawsuits as new legal arguments and scientific insights continue to shape potential outcomes and future settlements.

December 1, 2024 - Suboxone MDL Updates and Ongoing Concerns Over Severe Dental Side Effects

As of November 25, 2024, significant developments have occurred in the litigation concerning Suboxone, particularly regarding its association with severe dental issues.

Multidistrict Litigation (MDL) Status

The Suboxone lawsuits have been consolidated into a multidistrict litigation (MDL) in the Northern District of Ohio under Judge J. Philip Calabrese. As of November 2024, the MDL comprises 678 active cases, reflecting ongoing legal actions against Indivior, the manufacturer of Suboxone.

Recent Court Orders

On November 5, 2024, Judge Calabrese issued a new census order requiring all plaintiffs with cases filed by October 7, 2024, to submit key information, authorizations, and records via a Rubris Crosslink system. This order outlines steps for plaintiffs to establish and verify their use of brand-name Suboxone Film and the dental injuries linked to its use.

Allegations Against Indivior

Plaintiffs allege that Indivior failed to adequately warn users about the risk of severe dental problems, including tooth decay, erosion, and loss, associated with Suboxone. They claim that the company prioritized profits over consumer safety by not informing users of these potential side effects.

Patients are advised to consult product liability lawyers to fully understand their rights after suffering the side effects of Suboxone.

The litigation is ongoing, and further developments are expected as cases proceed through the legal system.

November 1, 2024 - Indivior Settles $85 Million Suboxone Fraud Case Before Trial

In a notable development in opioid litigation, pharmaceutical company Indivior agreed to pay $85 million to settle claims of healthcare fraud and antitrust violations related to its opioid-dependence drug, Suboxone. This settlement, reached just days before a five-week trial began in Roanoke County Circuit Court, is among the most prominent pharmaceutical “opt-out” settlements in recent history.

In this case, five health care benefit plans, the plaintiffs alleged that Indivior engaged in a “product hop” scheme by shifting the market from Suboxone tablets to a new film formulation in 2010. They argued that this tactic was designed to block generic competition and force healthcare plans to continue paying higher prices for the drug. A whistleblower within Indivior first exposed the scheme, which led to the plaintiffs filing suit in 2020 after opting out of the broader Suboxone multidistrict litigation (MDL).

In October 2023, a jury sided with the plaintiffs on a statute of limitations defense, ruling that their claims against Indivior were not time-barred. This verdict cleared the $85 million settlement path, highlighting ongoing scrutiny of anti-competitive practices in the pharmaceutical industry.

October 14, 2024 – Suboxone MDL Status Conference Update

Earlier this month, the court held a two-day status conference for the Suboxone MDL. The focus was on putting together a plan for the upcoming bellwether trials, which will play a key role in settling the Suboxone lawsuits.

These trials show how juries might react to the main issues, like claims about flaws in the product, lack of warnings, or misleading ads for Suboxone. How these test trials turn out often steers settlement talks and gives a peek into who might be held responsible. 

Legal experts agree there's a good shot the defendants might choose to settle before these trials start to avoid unfavorable jury decisions. But setting trial dates is key to getting settlement talks going. Getting these trials scheduled could help lead to a swift, comprehensive settlement in the Suboxone litigation.

We're closely monitoring things and will give you updates as we learn more.

October 1, 2024 - Court Issues Guidelines for Suboxone MDL Discovery

A recent case management order in the Suboxone multidistrict litigation (MDL No. 3092) outlines the protocols for electronic discovery (ESI) and document production. This includes how parties will handle digital and physical documents to streamline litigation. The court emphasized the need for efficiency while safeguarding privacy and privileged information. This order aims to reduce delays and ensure compliance as the litigation grows. It reflects the importance of organization and cooperation in large-scale legal actions like the ongoing Suboxone lawsuits.

September 27, 2024 - New Filing by Suboxone Plaintiff Leadership Committee Presents Airtight Arguments for Court Dismissing Preemption Claims

We have significant news regarding the ongoing Suboxone litigation, which could seriously help the plaintiffs' case after the defense filed a motion to dismiss based on "implied preemption."

In response to this motion, the Plaintiff Leadership Committee (PLC) has submitted a brief to the court that argues that Suboxone state law claims should not be dismissed under the doctrine of implied preemption unless Congress has explicitly enacted such preemption. To support this position, the plaintiffs point to two key legal developments: the recent Supreme Court decision in Loper Bright v. Raimondo and the Third Circuit of Appeals ruling in the Fosamax case.

In Loper Bright v. Raimondo, the Supreme Court's ruling challenged implied preemption in state-level claims without further proceedings that clarify the need for the preemption; they do not automatically apply. Additionally, the Third Circuit’s decision in Fosamax supports the PLC's argument since that court found that the lower court had made an error in applying preemption; the court ultimately sided with the plaintiffs and allowed state law claims to proceed. The main point here is that these rulings undermine the argument that statements from the FDA alone are sufficient to preempt state-based claims, the Suboxone failure to warn and design defect claims.

The PLC hopes the court will take these new rulings into consideration and allow the plaintiffs' state law claims to remain in the case and allow them to move past the defense's motion to dismiss.

Check back as we will continue to keep you updated on any major developments in this important part of the Subsone MDL.

September 1, 2024 - Plaintiffs Counter Indivior's Motion to Dismiss with Detailed Response

After Indivior submitted a Motion to Dismiss in the ongoing Suboxone MDL, the plaintiffs promptly filed their own motion. This motion challenges Indivior's attempt to dismiss the case, focusing on arguments related to federal preemption. Indivior's defense centers on the claim that federal law, particularly FDA regulations, precludes the state-level liability claims brought by the plaintiffs.

The plaintiffs, however, argue that their claims are not preempted because they involve new information about Suboxone's risks that Indivior allegedly failed to address in its product labeling. Under the FDA's Changes Being Effected (CBE) regulations, drug manufacturers can update their labels with new warnings based on emerging risks without prior FDA approval. The plaintiffs contend that Indivior had sufficient evidence of these risks well before the FDA’s updated label in June 2022 but did not take the necessary steps to update their labeling or warn users.

Furthermore, the plaintiffs assert that their design-defect claims are valid. They argue that an alternative delivery system for buprenorphine, such as the FDA-approved injectable Sublocade, could have reduced the risks associated with Suboxone film. They believe Indivior should have considered this alternative before bringing Suboxone film to market.

This response highlights the plaintiffs' stance that Indivior had an ongoing obligation to monitor, update, and address risks related to Suboxone, a responsibility they argue was neglected. The outcome of this legal battle will significantly impact the future of pharmaceutical litigation, particularly in cases where federal and state law intersect.

August 24, 2024 - Indivior's Motion to Dismiss in Suboxone Lawsuit

Indivior recently filed a motion to dismiss much of plaintiff Ryan Bennett's claims. If successful, this motion could apply to all Suboxone lawsuits pending in federal court. However, the good news is that this motion to dismiss is baseless and a mere formality that occurs in every mass tort.

Indivior's motion to dismiss is based on the doctrine of federal preemption. The doctrine of federal preemption essentially means that when federal law conflicts with state law, the court will defer to federal law or the intent of such. Essentially, Indivior contends that the label for Suboxone film was approved and thus is clearly adequate. However, a manufacturer remains responsible for their label at all times. 

In this case, Indivior has access to newly acquired information that should have prompted the manufacturer to amend their warning label to inform patients and physicians that prolonged exposure could lead to serious dental injuries. Indivior clearly has access to a growing body of adverse event reports that are filed with the FDA each year. These adverse event reports consistently demonstrate tooth loss and tooth erosion and destruction of tooth enamel. However, these folks constantly suffered severe dental injuries. 

Additionally, Indivior attacks Ryan Bennett's design defect claims. The design defect claim states that there are safer alternative delivery systems than sublingual buprenorphine. Indivior claims this is mere speculation as to what the FDA would do. However, the FDA already approved Sublocade (an injectable form of buprenorphine). 

We believe the Suboxone tooth decay lawsuit remains in great shape, and Judge Calabrese will almost certainly deny Indivior's motion to dismiss. The next stage of the Suboxone lawsuit is discovery to ferret out general and specific causation. 

August 18, 2024 - Suboxone Lawsuit Update: Published Research Paper Undermines Suboxone Film Warning Label

Indivior changed the label for Suboxone film in June of 2022. Less than six months later, a research paper was published that readily demonstrates how defective the label truly is. The research letter was published in the Journal of the American Medical Association and found a substantial increase in adverse dental injuries in individuals who used sublingual buprenorphine as compared to individuals using transdermal buprenorphine or oral naltrexone. 

Individuals who used sublingual buprenorphine for a prolonged period of time demonstrated a steady decline in dental health. In fact, these individuals had a greater number of tooth extractions, severe dental decay, tooth fractures, tooth erosion, and tooth loss.

This paper will serve as evidence in the Suboxone lawsuit that Indivior had access to information that should have prompted a manufacturer to change their label. In this case, Indivior should have changed the label to inform users of prescribed Suboxone film and physicians who regularly prescribe such that prolonged exposure could lead to significant dental injuries. 

August 15, 2024 - Statute of Limitations in Suboxone Tooth Decay Lawsuit 

Dolman Russo is taking the position that the June 2022 label change does NOT serve as a basis for an existing statute of limitations.  Thus, we are now reviewing potential Suboxone lawsuit claims from individuals in all fifty states. 

It is our opinion that an insert is the weakest form of a warning. Indivior buried warnings or information that would educate individuals about the dangers of Suboxone film deep within an insert. Further, Indivior failed to send a "Dear Doctor" letter to physicians who regularly prescribe Suboxone films. It is our opinion that Indivior failed to adequately warn both individuals and physicians of the likelihood that prolonged exposure to Suboxone film could lead to severe dental injuries. 

August 7, 2024 - Joint Status Report Filed in Suboxone Tooth Decay Lawsuit

A joint status report was filed in the Suboxone lawsuit, which is a great indicator that both parties may have reached, or are close to, a consensus on the Suboxone MDL tolling agreement. The defense has submitted a proposed order for the plaintiffs to review and is awaiting feedback on the terms. The plaintiffs are expected to respond within a week or so. I expect that we will hear something early to mid-next week. So keep an eye out on this page, or check Lawsuit Legal News's Subxone page for all the latest updates.

August 6, 2024 - Is the Pending Tolling Agreement Causing a Drop in Active Cases?

In the past month, the number of active Suboxone MDL cases dropped from 677 to 673. This decrease could be related to the Tolling Agreement both sides are working on, which would extend the filing deadlines for injured plaintiffs into 2025. The team at Dolman Law Group is anxiously waiting for the final Tolling Agreement and the MDL court's ruling on the defendant's motion to dismiss, described in our last update on August 1st.

August 1, 2204 - Suboxone Maker Files for Partial Dismissal

Indivior, the manufacturer of Suboxone, filed a Motion to Dismiss based on several legal arguments. First, they claim federal law controls any drug design changes, so they are not responsible for changing Suboxone's formulation after the drug was approved.

Also, the defendant argues that the FDA determined the drug was safe and effective when it was approved, and there is no new information that would require further user warnings. Indivior also raises a general argument that the plaintiffs' allegations are not sufficient to state a legal claim against it.

We will follow this motion closely and report when the court makes a ruling.

July 3, 2024 - Update on Number of Suboxone Cases Added in June

In June, the number of Suboxone tooth decay lawsuits increased dramatically. 319 new cases were filed, raising the number of lawsuits from 358 to 677. This shows that more people are coming forward with their claims against Suboxone, and the federal case is growing quickly.

June 24, 2024: Plaintiffs Win Causation Issue in Suboxone MDL

This week, the court decided against the defendants and in favor of the plaintiffs on an important causation issue. The defendants wanted to focus only on general causation issues, which would delay investigating the specifics of individual cases.

The plaintiffs argued against this, saying it would drag out the lawsuits and waste resources. But thankfully, the judge said that splitting general causation from other issues would be complicated and inefficient and that doing all the discovery together would help the Suboxone lawsuits move forward more smoothly.

June 25, 2024 - Revised Master Complaint Filed by Plaintiffs in Suboxone Case

The plaintiffs' leadership committee has submitted an amended master complaint to the Court in an ongoing effort to enhance the specificity of the claims so that there is a clearer framework for the discovery phase of the MDL. The updated complaint offers a detailed plan for how plaintiffs will substantiate their allegations against Indivior. As the discovery phase gets closer, this move is all about streamlining the process and strengthening the plaintiffs' position.

The litigation is waiting on Judge Calabrese's decision on the general and specific causation discovery debate, which has been a major part of the case so far.

June 11, 2024 - Court Hears Arguments About Bifurcating Causation Discovery, Two Groups of Suboxone Cases Created

On June 10th, Judge Calabrese heard arguments from both sides about whether these lawsuits should first focus on general causation evidence before addressing specific causation issues.

The defendant Indivior wants to limit the discovery of relevant evidence to the general causation question: Does Suboxone use cause dental problems? As a result, discovery related to specific causation evidence—how each plaintiff's use of Suboxone led to their dental issues—would be delayed.

The mass tort team at Dolman Law Group believes Indivior simply wants to drag out these cases, frustrate the plaintiffs and their lawyers, and run up litigation expenses for the law firms. and pressure injured Suboxone users into giving up. We hold firm that when the FDA changed the warning label on sublingual Suboxone in 2022, there was a solid causal link between using sublingual Suboxone and adverse dental conditions. Hopefully, the judge will deny the defendant's request and allow the MDL to proceed on both causation issues.

Also, plaintiffs' cases are now divided into two lists - those filed by plaintiffs in New Jersey, Delaware, and Virginia and those filed by plaintiffs from all other states. For federal jurisdiction, the plaintiff and defendants must have jurisdictional diversity. This means the parties cannot "reside" in the same state. Since the named defendants in these cases are located in New Jersey, Delaware, and Virginia, plaintiffs from those states would normally have to file their lawsuits in state court, and they wouldn't qualify for the federal MDL.

Under the recently entered tolling agreement, plaintiffs from those three states now have more time to decide whether to file a state or federal lawsuit and will not lose their legal rights due to the passage of time.

May 30, 2024 - Plaintiffs Oppose Phased Discovery in Growing Suboxone Tooth Decay MDL

Plaintiffs in the Suboxone MDL are urging the court to reject a defense proposal to split the litigation into two phases.

This would hold off on initial discovery into individual claims and instead focus on general causation. Plaintiffs argue this would unnecessarily delay the claims and justice for the victims.

As you likely know by now, the JPML centralized the lawsuits to coordinate pretrial proceedings and early bellwether trials.

However, Indivior's proposal to bifurcate discovery would defeat some of the purposes of an MDL by slowing down the case, delaying case-specific discovery, and wasting time on proving general causation.

Plaintiffs argue that this approach assumes that the defendants will win, which we believe is unlikely given the extensive scientific evidence linking Suboxone to tooth decay.

On May 24, plaintiffs filed an opposition brief stating that phased discovery would unnecessarily prolong the MDL and waste resources.

They also noted that most MDL courts avoid bifurcation because of this very reason. Judge Calabrese has ordered the defense to respond by May 31 and has scheduled oral arguments on the bifurcation/phased discovery proposal for June 6.

May 27, 2024 - Court Issues Two New Orders Pertaining to Procted Privileged Information

Recently, the Judge overseeing the Suboxone MDL issued two important Case Management Orders related to protected and privileged information. Here’s a brief overview of each order.

Case Management Order No. 5: Designation and Handling of Protected Information

This order outlines how to handle protected information in the Suboxone lawsuit. It defines "Confidential Information," "Highly Confidential Information," and "Protected Data." It specifies who can access these materials and how to label and manage them. It includes procedures for marking these documents, handling any errors, protecting personal data, and addressing breaches or the need to share confidential information in open court.

Case Management Order No. 6: Evidence Rule 502(d) and Privileged Materials

This order focuses on handling privileged materials in the Suboxone MDL. It applies Rule 502(d) of the Federal Rules of Evidence, which protects a person from waiving confidentiality when they share privileged information during the case. This rule allows parties to share information without losing legal protections like attorney-client privilege. This ensures any purposely or mistakenly disclosed information remains protected.

Both Case Management Orders No. 5 and No. 6 will remain in effect until the court modifies or terminates these orders.

May 20, 2024 – Judge Finds Compromise on Tolling Agreement Issue

On May 13, Suboxone's defense team officially rejected the tolling agreement, which would have allowed plaintiffs to file lawsuits after the statute of limitations expired so they could vet the cases before adding them to the MDL. This would not have allowed new claims to come in after the deadline but would have allowed cases that occurred before the deadline to be delayed in filing. It was not a huge ask, but Indivior wants to pay as few people as possible, so it's in their best interest to have cases refused due to a technicality.

As we mentioned, the tolling agreement would have also helped the Court and maintained the integrity of the MDl. Perhaps because of this, Judge Calabrese adopted a procedure we last saw used in the Xarelto case, where the plaintiffs must submit a master list by the deadline and then file all their cases at a later deadline.

For states with a two-year statute of limitations, the cut-off date for Suboxone lawsuits is June 14, 2024. Therefore, the Judge ruled that the plaintiffs’ lawyers must file a master MDL list of all individual plaintiffs by that date. The defendants will then have until July 1, 2024, to file a motion for severance.

This approach aims to reduce the court’s burden from a sudden influx of cases and provide a structured process for addressing the statute of limitations issue. We will provide you with more details after the next hearing.

May 13, 2024 – Indivior Officially Denies Tolling Agreement

Suboxone’s lawyers have finally explained their refusal to consent to a tolling agreement in the MDL. Today, the defense filed an opposition brief that made clear that a tolling agreement is not in their best interest. Basically, they recognized the benefits of the tolling agreement, but since it's not in their interest, they would prefer the SOLs to expire in 2-year states.

In their brief, they stated, “Defendants would get no benefit other than purported proof of use of Suboxone film, untethered to causation and purported damages.”

Plaintiffs argued that a tolling agreement would be fair to consumers and prevent Indivior from having to litigate in multiple jurisdictions due to varying statutes of limitations. Despite our expectations that Indivior might agree to avoid multi-jurisdictional litigation, it is now clear they will not.

This decision will push more cases toward state courts rather than the consolidated federal MDL, more or less defeating its purpose. The Judge may have something to say about this since it will so greatly affect the Court's time and money too.

May 1, 2024 - Focus on Order of Discovery and Potential Tolling Agreement at Latest Hearing in Suboxone Lawsuit 

We gained a little more insight into the case's progress at the last status conference for the Suboxone lawsuit MDL. Jude Calabrese held the latest status conference in the Suboxone lawsuit last week in the United States District Court for the Northern District of Ohio. Arguments were preferred in chambers by both parties concerning the order in which discovery wiki be conducted. 

Indivior is aggressively advocating for discovery solely on general causation before both parties turn their attention to specific causation. This is nothing more than a glorified stall tactic by the defendant manufacturer. This would result in adding a year to perhaps eighteen months to the duration of the Suboxone tooth decay MDL. 

Plaintiffs have the burden of illustrating through sound scientific evidence that prolonged exposure to sublingual buprenorphine medications causes tooth loss, among other serious dental problems that require extensive dental procedures. 

As previously referenced in our last update, the FDA unilaterally forced Indivior to change its warning label in June of 2022. The change in warning label was prompted by an alarming number of adverse event reports filed by sublingual Suboxone users with the FDA, many of whom complained of tooth loss. There are also several peer-reviewed and published medical studies that illustrate a causal link between prolonged use of sublingual buprenorphine and serious dental problems.

We believe general causation will not be a difficult burden for plaintiffs to meet in the Suboxone lawsuit. Specific causation, on the other hand, will be much more difficult. Plaintiffs will have the burden of showing that a specific individual's use of Suboxone sublingual strips leads directly to their tooth loss. It is our opinion that Judge Calabrese will opt to move this lawsuit in a prompt manner and focus the litigation and discovery on whether plaintiffs can prove specific causation

Suboxone lawyers and defense attorneys from Indivior also discussed the potential for a tolling agreement at the last hearing. A tolling agreement would effectively suspend all existing statutes of limitations until a specified period of time or event occurs. This would allow plaintiffs to perfect their lawsuits and investigate any potential issues prior to filing a Suboxone lawsuit. Many lawsuits in states with a two-year statute of limitations were rushed into litigation to preserve the rights of their clients. 

A tolling agreement would preclude problematic lawsuits from being filed and prevent a waste of judicial economy. In turn, Indivior's defense counsel would no longer be forced to answer every last Suboxone lawsuit filed. This issue is going to be briefed by lawyers from both sides over the coming weeks.

April 26. 2024 - Indivior Attempts to Slow MDL Progress by Focusing on General Causation Instead of Plaintiffs' Specific Claims

Indivior, the company that manufactures Suboxone, wants the Judge to limit the current litigation to only focus on whether the drug can be scientifically linked to dental problems instead of considering whether specific plaintiffs can establish a link between their individual Suboxone use and tooth decay.

At Dolman Legal Group, we believe this tactic is simply meant to delay the litigation and frustrate the plaintiffs who need financial compensation to pay for their dental care. The theory is that, over time, some injured plaintiffs may eventually become desperate for money and accept any settlement offered to finalize their claims.

Indivior cites other Multidistrict Litigation situations in which plaintiffs were first required to provide proof that the product could harm users. However, the Suboxone MDL is different because Indivior allowed the FDA to place a warning on Suboxone related to tooth decay in 2022 without a fight. The fact that Suboxone now carries a warning about dental issues shows that Indivior and the FDA acknowledge a scientific link between using Suboxone and severe tooth decay.

A warning is usually only added to a drug label after enough users report medical issues and/or scientific studies corroborate the alleged problems. Rather than wasting time discussing general causation, our legal team hopes the court will consider both general and specific causation at the same time to resolve these matters as quickly as possible.

April 15, 2024 - Over 140 Suboxone Lawsuits now Filed in MDL

As we previously predicted, the Suboxone lawsuit has grown quickly because of the statute of limitations deadlines that affect certain states. Many of the law firms on the Suboxone plaintiff's steering committee have been furiously filing lawsuits to preserve the rights of individuals residing in states with a two-year statute of limitations. Unfortunately, injured Suboxone users who reside in states with a two-year statute of limitations will lose their right to file a lawsuit in June 2024. Many law firms are no longer accepting those cases. 

We anticipate the Suboxone lawsuit will inevitably exceed 500 plaintiffs by mid-summer, placing pressure on Indivior to reduce their overall exposure and potentially settle these cases over the next two years. 

Currently, we have limited our intake to clients who have lost three or more teeth or had three or more tooth extractions. While most prospective clients contacting our firm have begun to suffer severe tooth decay, we believe tooth loss is required for a sustainable claim. 

April 9, 2024 - 106 Lawsuits Filed in the Suboxone MDL, Statute of Limitations Expires in June for Two-Year Injury States

The Suboxone Multidistrict Litigation (MDL) was formed in February of this year and already contains 86 lawsuits filed by people who suffered severe tooth damage after using Suboxone sublingual strips. As we mentioned below, in June 2022, the FDA required Indivior, the maker of Suboxone, to change the warning label on this product. As a result, people who were injured by Suboxone and live in a state with a two-year statute of limitations must file their Suboxone lawsuit before June 2024. Unfortunately, we are too close to this deadline to accept any more cases from people living in two-year deadline states.

At Dolman Law Group, we have also narrowed the scope of the cases we can accept to make sure the strongest cases join the pending MDL. We are currently only working with Suboxone users who have suffered the loss or extraction of three or more teeth as a result of these strips. Tooth loss has become the driving factor behind Suboxone lawsuits. The overarching goal is not to flood the Northern District of Ohio with Suboxone product liability lawsuits alleging injuries that may have a number of confounding factors or are not considered significant by the defendant manufacturer.

March 22, 2024 - Dolman Law Group is Taking Michigan Suboxone Claims

Michigan Governor Gretchen Whitmer just signed a bipartisan bill into legislation that repeals a law that previously provided drug makers with absolute immunity from liability. Michigan had the only law in our nation that shielded drug manufacturers from product liability claims.

Michigan has a three-year statute of limitations for product liability claims. Thus, we will be accepting Michigan Suboxone tooth decay claims until late May 2025. We are now cutting off signing up Suboxone tooth decay cases from individuals residing in States with a two-year statute of limitations for product liability claims. Since the FDA forced Indivior to change its warning label for prescription Suboxone film in June of 2022, we are simply too close to the deadline expiring in two-year states to feel comfortable taking such cases.

March 12, 2024 - Initial Status Conference in the Suboxone Tooth Decay Lawsuit

Judge Calabrese held the first status conference of the Federal Suboxone lawsuit wherein he appointed a Plaintiff's Steering Committee with eighteen members, including Stanley Gipe from Dolman Law Group. We anticipate coordinated discovery will soon commence.  

Please note that Judge Calabrese has scheduled the next status conference hearing for April 16, 2024, at 2pm. Further, Judge Calabrese requested that both parties submit an agenda for the next status conference by April 11, 2024.

March 2, 2024 - Plaintiff Steering Committee Leadership Slate Has Been Submitted to Judge Calabrese

A leadership slate for the plaintiff's steering committee on the Suboxone tooth decay lawsuit has been submitted to Judge Calabrese. We are proud to announce that R. Stanley Gipe of Dolman Law Group/Dolman Russo is among the lawyers who will almost certainly comprise the plaintiff's steering committee.

The initial status conference in the Suboxone lawsuit is scheduled for Thursday, March 7, 2024, at 9 a.m., in front of the honorable Judge Philip Calabrese in the United States District Court for the Northern District of Ohio. 

We anticipate Judge Calabrese will likely approve the plaintiff's proposed leadership slate and begin coordinating discovery to commence between plaintiffs and defendants in the Suboxone lawsuit.

It is worth noting that we are quickly approaching the expiration of a statute of limitations for plaintiffs residing in states with a two-year statute of limitations for product liability claims. The warning label on Suboxone film was changed back in June of 2022.

March 1, 2024 - Suboxone Tooth Decay Lawsuit Slowly Grows in the Northern District of Ohio

Two new Suboxone lawsuits have joined the Suboxone MDL pending before Judge Philip Calabrese in the Northern District of Ohio. First, a Kentucky man who has used Suboxone sublingual films since 2011 alleges he was never warned about the potential harm he would suffer until 2023. He is requesting compensation for extensive dental expenses, pain and suffering, and irreversible damage due to Suboxone use.

The plaintiff is requesting compensation for extensive dental expenses, pain and suffering, and irreversible damage due to Suboxone use.

The second Suboxone tooth decay lawsuit was filed by an Ohio man who also experienced extensive dental issues requiring many painful dental treatment procedures. He claims his doctor was not aware of potential risks associated with sublingual buprenorphine, so he received no warning about Suboxone use.

We are presently representing hundreds of individuals who were prescribed Suboxone films and subsequently developed severe dental injuries, including severe tooth decay, tooth loss, tooth fractures, dental caries, and gum infection, among other oral health issues.

February 2, 2024 - All Federal Suboxone Lawsuits Consolidated Into an MDL

It's official… federal Suboxone lawsuits are consolidated into an MDL (multidistrict litigation). No oral arguments were heard at the JPML hearing since it wasn't necessary. Both sides agreed to consolidate the cases into an MDL before the hearing. Federal Judge J. Philip Calabrese from the Northern District of Ohio was appointed to oversee Suboxone litigation and all federal claims against Indivior for tooth decay and other serious oral health issues.

January 17, 2024 - Indivior Knew Suboxone Sublingual Films Increased Risk of Severe Tooth Decay

Apparently, Indivior, the company that manufactures Suboxone, knew about the potential risk that users could experience tooth decay since it is mentioned in the prescribing information provided to doctors. However, it appears they didn't think it was important enough to include in the medication guide, which warns patients about the potential side effects of a specific drug. We expect to learn more about the MDL decision after January 25.

January 16, 2024 - Lawsuit Against Suboxone Highlights Failure to Warn

A new Suboxone tooth decay plaintiff, Lindsay Haddad, has emerged as one of the thousands of Americans who suffered profound dental injuries after using the medication to reduce her dependence on opioids.

A new Suboxone tooth decay plaintiff, Lindsay Haddad, has emerged as one of the thousands of Americans who suffered profound dental injuries after using the medication to reduce her dependence on opioids. Her product liability lawsuit claims that Indivior effectively deprived the medical community of the information they needed to care for their patients properly, relied on insufficient testing to vet their medication, did not accurately inform consumers about the risks of using Suboxone, and manufactured the medication based on a defective design.

Her Suboxone lawsuit claims Indivior effectively deprived the medical community of the information they needed to care for their patients properly, relied on insufficient testing to vet their medication, did not accurately inform consumers about the risks of using Suboxone film, and manufactured the medication based on a defective design.

January 4, 2024 - Latest Suboxone Lawsuit Alleges Indivior Concealed the Harm

A Cuyahoga County woman has become the most recent plaintiff to file a Suboxone tooth decay lawsuit alleging the drug manufacturer Indivior concealed the risks of the medication from patients and providers.

A Cuyahoga County woman has become the most recent plaintiff to file a Suboxone tooth decay lawsuit alleging the drug manufacturer Indivior concealed the risks of the medication from patients and providers. Her complaint describes the significant tooth decay she experienced as a result of using Suboxone, which includes an active ingredient known to create the conditions for enamel erosion. Including this claim, over 15 plaintiffs have taken legal action against Indivior in federal court, although there could be hundreds more eligible plaintiffs across the country. Given the similarity of the Suboxone tooth decay claims and the potential for expansion, the parties have asked to consolidate the cases into multidistrict litigation (MDL). The defendants have suggested centralizing the Suboxone tooth decay lawsuits in the Northern District of Ohio, where Cuyahoga County is located.

Given the similarity of the Suboxone tooth decay claims and the potential for expansion, the parties have asked to consolidate the cases into multidistrict litigation (MDL). The defendants have suggested centralizing the Suboxone tooth decay lawsuits in the Northern District of Ohio, where Cuyahoga County is located.

January 3, 2024 - Suboxone Class Action Lawsuit Continues to Grow

More lawsuits are expected as the number of Suboxone tooth decay lawsuits continues to rise, with hundreds of potential cases being investigated by lawyers nationwide. This trend suggests that the issue of Suboxone-related dental problems is not likely to go away any time soon. As of January 3, 2024, there have been no announced settlements in any Suboxone tooth decay lawsuits.

Keep in mind that this class action lawsuit is in its infancy. A Suboxone settlement is unlikely to occur in 2024. We anticipate that all federal Suboxone tooth decay lawsuits will be consolidated by the Judicial Panel on Multidistrict Litigation (JPML) over the coming months.

A settlement in the Suboxone lawsuit will become more likely as discovery proceeds and plaintiff lawyers are able to demonstrate their experts can causally link the use of sublingual buprenorphine.

January 2, 2024 - Studies Illustrate Link Between Suboxone and Tooth Decay

More studies are emerging that support a link between Suboxone use and an increased risk of tooth decay. These studies seem to show that the drug changes the oral bacteria balance and decreases saliva production in the user's mouth, both of which can contribute to dental problems. Although the link between Suboxone and tooth decay is becoming clearer, the specific ways in which Suboxone affects the teeth and gums are still not exactly known. Further research is being done to understand the long-term effects and how dosage variations and oral hygiene techniques might curb these negative side effects.

December 26, 2023 - JPML to Discuss Consolidating Suboxone Lawsuits into an MDL

The Judicial Panel on Multidistrict Litigation (JPML) has scheduled their next hearing for January 25, 2024, in Santa Barbara, California, where they will hear arguments from both plaintiff and defense lawyers on whether all pending Suboxone teeth lawsuits pending in Federal Courts throughout the United States, should be consolidated in one jurisdiction as part of multidistrict litigation (MDL). We believe the JPML will consolidate the Suboxone class action lawsuit in the Northern District of Ohio.

December 4, 2023 - Plaintiff Lawyers File Petition With JPML to Consolidate the Suboxone Class Action Lawsuit 

The MDL motion alleges all of the claims filed against the drug manufacturer Indivior related to Suboxone injuries have similar facts and legal arguments, including the reason Suboxone is prescribed—for people struggling with opioid use disorder (OUD). However, Suboxone's film is acidic and connected to tooth erosion and dental decay, and Indivior should be held liable for manufacturing and selling Suboxone when it knew or should have known about these potentially dangerous side effects and harming users.

Plaintiffs also assert that since 2007, patients have been reporting dental issues, and research starting in 2012 has shown a potential connection between taking Suboxone sublingually (under the tongue) as prescribed and severe tooth decay. Also, even though it knew about these potential risks, Indivior failed to change the drug or warn about the risks. This is at the heart of allegations in Suboxone lawsuits.

November 17, 2023 - Petition to Create an MDL

Plaintiffs' lawyers petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all Suboxone lawsuits that have been filed in Federal Courts throughout the country into one jurisdiction.

The plaintiffs have asked the JPML to consolidate Suboxone lawsuits into the Northern District of Ohio. Considering that plaintiff David Sorensen filed the first Federal lawsuit linking the use of sublingual Suboxone to tooth decay in the Northern District of Ohio, we feel this is a likely jurisdiction for the Suboxone teeth lawsuits.

Suboxone lawyers are satisfied with the science (an easy causal link between Suboxone film use and issues related to dental health) and the back story on Indivior being a bad actor.

November 1, 2023 - New Lawsuits Filed Against Indivior

Four new Suboxone tooth decay lawsuits were filed against Indivior in federal courts over the past month. Each lawsuit alleges a physician prescribed Suboxone film to treat opioid addiction. Neither the plaintiff or his/her physicians were adequately informed of the risk associated with sublingual Suboxone film per allegations contained within each lawsuit.

October 30, 2023 - Indivior Faces Two Lawsuits, With New Accusations of Tooth Decay

Indivior now faces multiple avenues of litigation that they must now fight off. On one hand, Indivior must defend a False Claims Act lawsuit accusing the company of an illegal kickback scheme. At the same time, there is an ever-growing number of lawsuits alleging the use of Suboxone (film form) led to advanced tooth decay.

It is important to know that Indivior has denied any wrongdoing and is fighting these lawsuits in court. However, the sheer number of people with tooth decay who took Suboxone, along with scientific evidence, means there's a significant risk that Indivior will be found liable for their negligence.

Frequently Asked Questions About the Suboxone Lawsuits

---

What is Suboxone?

Suboxone is a medication—often prescribed in a film rather than a tablet, like the picture above—that aids individuals struggling with opioid addiction by making it easier for them to stop using the harmful drugs.

It works similarly to other opiates but in a way that doesn't make you feel "high." This can reduce cravings and withdrawal symptoms, making it easier to recover from opioid dependence or addiction. Attaching to the same parts of the brain that opioids stick to attaching to the same parts of the brain that opioids stick to

Suboxone is generally considered the best in class for opioid addiction treatment. Some individuals might get side effects from Suboxone, like nausea, headaches, and constipation. But if you notice anything concerning dental health, especially tooth decay, you should talk to a doctor.

Suboxone Tooth Decay Lawsuits

Suboxone tooth decay lawsuits involve claims against the manufacturers of Suboxone. Plaintiffs allege that the drug causes severe tooth decay and dental problems, which the manufacturer, Indivor, did not adequately disclose. The lawsuits argue that users experienced significant dental issues, such as complete tooth loss, because of the medication. These cases highlight the need for more explicit warnings and better information about the potential side effects of drugs.

It also asks, "What should be done when companies know about dangers but choose not to share the information to protect corporate profits?"

Why are People Filing Lawsuits 

Dental health problems linked to Suboxone have become a problem for those prescribed the medication. Many have reported some severe dental issues, including:

Severe Tooth Decay

This is one of the biggest issues, resulting in numerous cavities and damaging teeth, often resulting in emotional distress. The majority of cases we have seen so far are potential tooth decay lawsuits.

Tooth Erosion

Suboxone use might erode tooth enamel, making teeth more vulnerable to decay and sensitivity. As a result, patients can develop the following dental problems:

• Cavities
• Dental caries
• Dental crowns or crown replacement
• Tooth loss

Dry Mouth

Some people on Suboxone experience dry mouth as a side effect, leading to less saliva production. Saliva helps protect teeth from decay, so less of it can mean more dental problems. Saliva also protects against dental caries (the breakdown of the tooth).

Gum Problems

Suboxone might also cause gum issues, like inflammation, which can significantly impact dental health, and periodontal disease, which also has a profound impact on dental health.

Tooth Fractures/Broken Teeth

We are seeing numerous complaints of fractured teeth and cracked teeth supposedly caused by Suboxone film strips.

Infections

Many of the aforementioned dental problems also come with the risk of leading to infection. Mouth and dental infections are painful and costly and can potentially spread. Depending on the person, infections can also present severe risks if they are immunocompromised or elderly. Tooth infections can also spread to other parts of your head and cause infections, abscesses, blood infections, and even heart and kidney damage.

Tooth Loss

Tooth loss due to decay or infection occurs when a tooth or multiple teeth become severely damaged by decay or advanced dental infections. As the decay or infection spreads, it weakens the tooth structure and surrounding tissues, eventually leading to tooth loss. This type of tooth loss can cause severe pain, problems eating and chewing, and many other issues. Prompt treatment can prevent such outcomes, including fillings, root canals, or extractions.

Fixing these dental problems can be painful and expensive.

Allegations Against Indivior for Suboxone Tooth Decay

The lawsuits claim that Indivior didn't warn people enough about the risk that a user may suffer severe tooth decay linked to the opioid addiction treatment drug Suboxone. They also say that Indivior knew or should've known about the risk but didn't do enough to prevent it. Our Suboxone lawyers believe we will learn more over the coming months about how much Indivior knew about the risks of sublingual Suboxone film exposure years ago.

Evidence for Suboxone Causing Tooth Damage

The connection between prescription medication Suboxone use and tooth decay is based on reports and scientific observations. But we need more research to be sure. Here's what's been pointed out (potential side effects):

Evidence for Suboxone Causing Tooth Damage

The connection between the prescription medication Suboxone and tooth decay is based on reports and scientific observations. Although more research is needed to establish a definitive link, several potential side effects have been identified. Here’s a detailed look at the evidence:

Patient Reports

• Widespread Anecdotal Evidence: Numerous individuals taking Suboxone (the gold standard medication for treating opioid use disorder and curbing withdrawal symptoms) have reported significant dental issues, including tooth degradation, discoloration, and loss. These patient reports have been a primary driver in raising awareness and prompting further investigation into the dental side effects of Suboxone.
• Forums and Support Groups: Online forums and support groups for people recovering from opioid addiction often discuss dental problems associated with Suboxone use, indicating a pattern among users that warrants scientific scrutiny.

Dry Mouth Side Effect

• Saliva Production Reduction: Suboxone is administered sublingually (under the tongue), which can significantly reduce saliva production. Saliva is crucial for maintaining oral health as it helps neutralize acids produced by bacteria, wash away food particles, and provide disease-fighting substances.
• Consequences of Dry Mouth: The reduction in saliva leads to a condition known as xerostomia, which can increase the risk of tooth decay, gum disease, and oral infections. Patients often experience a higher incidence of cavities and other dental issues when their mouth remains dry for extended periods.

How Does Saliva Protect Your Teeth?

Saliva plays a crucial role in maintaining oral health and protecting teeth. It contains enzymes and proteins that help neutralize acids produced by bacteria, which can cause tooth decay. Saliva also washes away food particles and debris, reducing the risk of cavities.

It also provides essential minerals, such as calcium and phosphate, which help remineralize and strengthen tooth enamel. Saliva's lubricating properties facilitate easier swallowing and chewing, forming a protective coating on teeth, further shielding them from harmful substances. Overall, saliva is essential for preserving dental health and preventing oral diseases.

Acidic Nature

• pH Levels of Suboxone Strips: Suboxone strips have an acidic pH, typically around 3.5 to 4.5. This acidity can directly contribute to tooth enamel erosion, the protective outer layer of teeth.
• Enamel Erosion: Continuous exposure to acidic substances can weaken enamel, making teeth more susceptible to decay and sensitivity. Without diligent dental hygiene practices, the acidic nature of Suboxone can exacerbate these issues.

Medical Studies

• Preliminary Research Findings: Initial studies have suggested a correlation between the use of opioid medications like Suboxone and dental problems. These studies indicate that opioid use can negatively impact oral health, but more comprehensive research is necessary to confirm these findings and understand the mechanisms involved.
• Need for Further Research: Current research is limited and often anecdotal. Comprehensive, long-term studies are required to establish the connection between Suboxone and dental health issues, considering various factors such as dosage, duration of use, and individual patient differences.

While significant anecdotal evidence and some preliminary research suggest a link between Suboxone use and tooth damage, more rigorous scientific studies remain necessary. Suboxone patients should be aware of these potential side effects and take proactive measures to maintain oral health, including regular dental check-ups and proper dental hygiene practices.

Possible Punitive Damages

We believe Indivior knew just how acidic the sublingual strips of Suboxone are and how they can destroy a user's tooth enamel. Numerous adverse event reports have been received, including severe tooth decay, broken teeth, cracked teeth, and gum infections, among other issues related to the use of the Suboxone sublingual form.

Indivior's failure to warn consumers of such issues has resulted in the need for extensive dental treatment for many of the clients we represent. Thus, we believe punitive damages are warranted above and beyond compensatory damages in a Suboxone dental lawsuit.

Studies Connecting Suboxone to Tooth Decay

A few studies have looked into the connection between Suboxone and tooth decay. Some credible sources suggest that Suboxone might increase the risk of dental problems:

• One study in 2016 found that people taking Suboxone were more likely to get tooth decay than those who didn't.
• Another study found that Suboxone users had more cavities and tooth erosion than others.
• A 2022 study found that Suboxone users had a higher risk of dental issues compared to those taking other meds for opioid use disorder, especially if they had dental problems before starting Suboxone. There was a large increase in the risk for adverse dental outcomes.

Potential Injuries in a Suboxone Case

• Tooth Enamel Loss
• Cavities
• Cracked Teeth
• Tooth Decay
• Infections
• Tooth Loss and Extraction
• Total Tooth Loss

FDA's Response to Suboxone Tooth Decay

In 2022, the FDA warned about the risk of dental problems linked to buprenorphine (Suboxone). Some people had severe oral issues like tooth decay, cavities, infections, and tooth loss, even if they'd never had dental problems before and maintained good dental hygiene.

According to the FDA, increasing medical research and reports connect the dissolvable sublingual film with dental problems. So, the FDA told manufacturers to include warnings about these dental risks in the prescribing information and the patient medication guide.

We believe the drug maker Indivior, Inc. failed to include adequate warnings the sublingual film version of this prescription drug could cause serious dental health issues.

Statute of Limitations for the Suboxone Dental Decay Lawsuit

July 7, 2024 update - We are now taking cases in every state and will argue that the warning in the insert for Suboxone film is hardly a warning. Further, Indivior has never provided a "Dear Doctor" letter to physicians to prescribe Suboxone film, which would have placed such medical professionals on notice of the potential dental injuries related to the medication.

The statute of limitations in mass tort cases is one of those things that is always a concern. For example, lots of people took the medication years ago and are just now finding out about all the damage it caused. Or, maybe five years ago, they suffered severe dental problems, but they didn't know it was because of Suboxone films.

The statute of limitations for the Suboxone Tooth Decay Lawsuit depends on the state in which you live and the specific circumstances of your case.

Specifically, it depends on the window of opportunity established by the statute of limitations for defective drug cases or product liability cases in your state. And whether or not your specific circumstances will allow a lawyer to still file a lawsuit on your behalf, even if the deadline may have passed. For example, if your dental injuries just started showing, a lawyer may be able to work with you.

It should be noted that in a lot of states, the statute of limitations may have run out since Indivior added a warning to Suboxone film in January 2022.

Calling the LLN Suboxone Lawyers is the quickest way to find out, but there is a breakdown of each state and its statute of limitations pertaining to defective drugs or product liability. Those states in bold have reached or are very near the end of their statute of limitations. Please refer to this list if you are considering filing a Suboxone lawsuit.

• Alabama Statute of Limitations for Defective Drug Case: 2 Years
• Alaska Statute of Limitations for Defective Drug Case: 2 Years
• Arizona Statute of Limitations for Defective Drug Case: 2 Years
• Arkansas Statute of Limitations for Defective Drug Case: 3 Years
• California Statute of Limitations for Defective Drug Case: 2 Years
• Colorado Statute of Limitations for Defective Drug Case: 2 Years
• Connecticut Statute of Limitations for Defective Drug Case: 2 Years
• Washington D.C. Statute of Limitations for Product Liability: 3 Years
• Florida Statute of Limitations for Product Liability: 4 Years
• Delaware Statute of Limitations for Product Liability: 2 Years
• Georgia Statute of Limitations for Defective Drug Case: 2 Years
• Hawaii Statute of Limitations for Product Liability: 2 Years with discovery rule
• Idaho Statute of Limitations for Product Liability: 2 Years
• Illinois Statute of Limitations for Product Liability: 2 Years
• Indiana Statute of Limitations for Product Liability: 2 Years
• Iowa Statute of Limitations for Product Liability: 2 Years
• Kansas Statute of Limitations for Product Liability: 2 Years
• Kentucky Statute of Limitations for Product Liability: 1 Year with discovery rule
• Louisiana Statute of Limitations for Product Liability: 1 Year
• Maine Statute of Limitations for Product Liability: 6 Years
• Maryland Statute of Limitations for Product Liability: 3 Years
• Massachusetts Statute of Limitations for Product Liability: 3 Years
• Michigan Statute of Limitations for Product Liability: 3 Years
• Minnesota Statute of Limitations for Defective Drug Case: 6 Years
• Mississippi Statute of Limitations for Product Liability: 2 Years
• Missouri Statute of Limitations for Product Liability: 5 Years
• Montana Statute of Limitations for Product Liability: 3 Years
• Nebraska Statute of Limitations for Product Liability: 2 Years
• Nevada Statute of Limitations for Product Liability: 2 Years
• New Hampshire Statute of Limitations for Product Liability: 3 Years
• New Jersey Statute of Limitations for Product Liability: 2 Years
• New Mexico Statute of Limitations for Product Liability: 3 Years
• New York Statute of Limitations for Product Liability: 3 Years
• North Carolina Statute of Limitations for Product Liability: 3 Years
• North Dakota Statute of Limitations for Product Liability: 10 Years
• Ohio Statute of Limitations for Product Liability: 2 Years
• Oklahoma Statute of Limitations for Product Liability: 2 Years
• Oregon Statute of Limitations for Product Liability: 2 Years
• Pennsylvania Statute of Limitations for Product Liability: 2 Years
• Rhode Island Statute of Limitations for Product Liability: 3 Years
• South Carolina Statute of Limitations for Product Liability: 3 Years
• South Dakota Statute of Limitations for Product Liability: 3 Years
• Tennessee Statute of Limitations for Product Liability: 1 Year with discovery rule
• Texas Statute of Limitations for Product Liability: 2 Years
• Utah Statute of Limitations for Product Liability: 2 Years
• Vermont Statute of Limitations for Product Liability: 3 Years
• Virginia Statute of Limitations for Product Liability: 2 Years
• Washington Statute of Limitations for Product Liability: 3 Years
• West Virginia Statute of Limitations for Product Liability: 2 Years
• Wisconsin Statute of Limitations for Product Liability: 3 Years
• Wyoming Statute of Limitations for Product Liability: 4 Years

Compensation for Suboxone-Related Tooth Decay

People who've had severe tooth decay or other mouth problems because of Suboxone might be able to get some compensation. The amount depends on the extent of the dental damage and the case details.

Compensation for tooth problems related to Suboxone film use could include:

• Medical Bills
• Dental Bills
• Pain and Suffering
• Lost Wages
• Future Medical Costs
• Emotional distress
• Punitive damages

Read more: How much can I get in a Suboxone settlement?

Indivior's Questionable Past as a Bad Actor

Indivior agreed to a $385 million settlement in October to resolve a series of lawsuits that accused it of illegally attempting to maintain its monopoly over Suboxone, a medication used to treat opioid addiction.

In June, Indivior agreed to pay a settlement of $102.5 million to dozens of U.S. states for the monetary damage they incurred through state-based healthcare programs. And, in August, they also agreed to pay $30 million to settle a similar class action lawsuit by health insurance companies.

These lawsuits show that Indivior is no stranger to serious accusations.

More to the point, this lawsuit and others like it filed against Indivior also bolster claims that Suboxone strips did not have a warning about tooth decay because the product was rushed to market to help maintain the monopoly addressed in this lawsuit, presumably.

The lawsuits allege that Indivior attempted to extend its monopoly by changing Suboxone from a tablet form to a sublingual film version to deter generic competition by convincing doctors and patients that new—and still Indivior-owned—films were more effective and convenient for users, making them a better choice than the tablets.

This was never proven to be the case, but today, the sublingual film version of Suboxone completely dominates the market, even now that both tablet and film patents are up. Their marketing worked: strips have dominated tablets in Suboxone treatment.

Indivior settled without admitting any wrongdoing and concluded nearly ten years of constant litigation.

That is, until it was discovered that they failed to warn patients that Suboxone can cause possible tooth decay, whether or not it was caused by rushing to maintain their monopoly.

Talk To a Suboxone Lawyer Today

Lawsuit Legal News is ready to help you get the compensation you need for your dental problem caused by Suboxone. Our associated law firm, Dolman Law Group, has fought back against some of the biggest drug companies in the world, like 3M, Chemguard, Chevron, Tyco, Dupont, Tylenol, and Ozempic, and we are ready to take on Indivior.

If you suffer from or have suffered severe tooth decay, tooth loss, fractured teeth, root canal, or persistent cavities after using the sublingual form of Suboxone film, we would like to speak with you.

Our Suboxone lawyers remain ready, willing, and able to assist you with handling your claim and the inevitable filing of a lawsuit against Indivior. Dealing with opioid dependence is a significant ordeal by itself. Having to tackle an opioid use disorder and withdrawal symptoms while dealing with poor dental health is quite a burden.

We have built a national reputation for litigating against every major pharmaceutical company that has injured patients taking their drugs. The Dolman lawyers affiliated with Lawsuit Legal News have taken on drug manufacturers nationwide.

Our Suboxone tooth decay lawyers offer a free consultation and case evaluation to anyone suffering from tooth loss, severe tooth decay, tooth erosion, gum disease, and other dental injuries or tooth issues following long-term use of Suboxone. Contact us for a free consultation if you have a potential lawsuit.We are handling Suboxone tooth decay cases nationwide. Contact us immediately at (833) 552-7274.

Maintaining Oral Health and Recognizing Early Signs of Tooth Decay

Taking care of your teeth is important; we all know this. It’s the only set you get. But it’s even more important when you are on Suboxone, which is why we have covered some important information below. Additionally, knowing what to look for when it comes to tooth decay while you are on Suboxone is extremely important.

Taking Care of Your Teeth While Taking Suboxone

Keeping your teeth healthy while taking Suboxone is important. Keep in mind how Suboxone causes tooth decay, like dry mouth, acid, and bacteria growth, and make sure to prevent as many of these side effects as possible.

1. Brush thoroughly twice a day: Use a soft-bristled toothbrush and toothpaste to protect your teeth from decay. Soft bristles will help prevent further damage, and the fluoride in the tooth will help combat the effects of acid on your tooth enamel.
2. Floss daily: Flossing removes plaque and food particles from places your toothbrush can’t reach. This is crucial since Suboxone can reduce saliva flow, making your mouth more prone to bacteria buildup and more likely for food to stick between your teeth.
3. Increase water intake: Dry mouth is a common side effect of Suboxone, so staying hydrated will help keep your mouth moist and protect against tooth decay. Keep a bottle of water with you so that you can always keep your mouth wet.
4. Eat a balanced diet and limit acidic drinks: Foods high in sugar and acidic beverages can further damage your tooth enamel, especially since Suboxone contains sweeteners and is acidic. So if you’re a soda or coffee drinker and on Suboxone (which, face it, you probably are), make sure you use that water from step three to rinse your mouth.
5. Visit the dentist regularly: Whether you are taking Suboxone or not, you should obviously visit your doctor at least twice a year. But if you are taking Suboxone, you should make sure to tell your dentist so they can keep an extra close watch on your oral health. They may also be able to offer specific advice or treatments to counteract Suboxone’s effects on your teeth, like a specialized mouthwash to help with dry mouth.

Rinse Your Mouth After Taking Your Subxone Films

The directions for sublingual Suboxone films instruct the user to put the medicine in their cheek or under the tongue and to wait for it to dissolve; based on studies and anecdotal reports, this usually takes around 10-15 minutes. The patient is instructed to not drink or eat anything for 30-45 minutes after the medicine dissolves.

Suboxone’s instructions also mention that if you are required to take three or more strips, wait until the first two dissolve on each side of the mouth and then place the third strip in your mouth and repeat the process.

This means that the film strips and the dissolved Suboxone residue could be in your mouth for 1 hour or more, exposing your teeth to an extremely acidic environment.

An extreme but fair analogy would be something like taking a sip of vinegar and then holding it in your mouth for 30-60 minutes. If you try this—or if you take Suboxone—rinse your mouth out afterward so that you can remove the acid and return your mouth to its regular pH.

After reading this particular section, consider how many Suboxone users were unaware of any of this because it was not told to them or their doctors. Think how many people went to bed with a Suboxone strip in their mouth or tooth their medicine three times a day for years and never rinsed afterward because they didn’t know any better. This is where the failure to warn accusations against Indivior really hit home.

Preserving Evidence for Your Suboxone Tooth Decay Case

If you have severe tooth decay because of taking Suboxone, you need to preserve evidence so that your lawyer can build a strong case for you. Here’s what you can do to make sure you have the best chance possible at winning your case and getting compensation:

Gather Your Suboxone Prescriptions

Try to find any of your Suboxone prescriptions that you can and keep all your future prescriptions. You can also contact your doctor and pharmacist to see if they can help you get copies. Documentation of your Suboxone prescriptions shows your dosage and changes in dosage, how long you’ve been on Suboxone, and other details.

Maintain Dental Records

Don’t forget to continue your regular dental checkups and keep all your records. You should also try to get your past dental records, including X-rays, diagnoses, and treatment plans related to your tooth decay. These documents will show the extent of your dental damage and help provide a timeline of your issues. And, if you’ve had any major procedures because of your dental decay, keep the receipts and any related paperwork.

Document Doctor Records

If you ever talked to your doctor or dentist about how Suboxone is impacting your teeth, keep copies of any paperwork or notes from those conversations. You can also get copies from your doctors or dentists. Not only can this help provide context for your condition, but if you brought up any issues, it can also potentially show documentation if you raised any concerns and weren’t informed about the risk of Suboxone causing dental problems.

Take Photos

You should also take clear photos of the damage to your teeth. Any photos will be helpful, but if you can get pictures as your dental decay progresses. This will help the jury or defendants see the extent of your decay and understand the impact on your life.

Keep Receipts for Dental Expenses

Keep receipts of what you paid for dental procedures and anything else related to costs that show how much you spent treating your tooth decay. These will be used to document the financial burden you’ve experienced.

Maintain a Journal

If you realize what is happening soon enough, write about it in a journal or keep notes about your experience on your phone. Keep track of the dates you started and stopped taking Suboxone, any symptoms you experience related to your teeth (like dry mouth, increased sensitivity, cavities, etc.), and anything you talked to your doctor about. Really, this step, and all the others, is about gathering as much evidence as possible to show your negative experience with Subxone and tooth decay.

Speak to a Lawyer

Don’t be discouraged if you’re missing some of the above evidence. A Suboxone lawyer can still offer valuable guidance, help to prove your case, and use expert witnesses to prove how Suboxone caused your tooth decay.

Talking to a lawyer about your case is one of the most important things you can do to ensure you get compensation for your tooth decay. This is different from the kind of lawsuit you can handle alone. Matt Dolman, Stan Gipe, and all of Dolman Law Group have been taking on giant corporations and pharmaceutical companies for decades. We have the expertise and resources to take on Suboxone and Indivior, precisely what we are doing.

---

1. The infographic is the sole property of Lawsuit Legal News and cannot be used, copied, or downloaded without LLN's consent. You may, however, link to the infographic. ↩︎